The global HPV and Pap test market size is expected to reach $7. 1 billion by 2027, with the market growing at 33.5% CAGR during the forecast period. Pap tests and HPV testing are both included in cervical cancer screening, which is a crucial part of a woman’s routine health checkup as it can detect cancer or abnormalities that may lead to cervical cancer.
New York, Aug. 31, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Regional Outlook, Industry Analysis Report and Forecast , 2021 – 2027″ – https://www.reportlinker.com/p06131317/?utm_source=GNW
It is suggested that a woman should have a Pap test every 3 years starting at the age of 21. In addition, it is also recommended that women between the ages of 30 and 65 have a Pap and HPV test every 5 years or a Pap test in 3 years. Women with certain risk factors may require more frequent screening or continue to be screened even after age 65.
Some of the determinants driving the demand and growth of HPV test and Pap test are constant technological developments, increasing number of cervical cancer screening programs and increasing cases of cervical cancer . On the other hand, the global COVID-19 crisis and the imposition of various lockdown norms and restrictions to keep people at home have drastically reduced routine cancer screenings.
Impact of COVID-19
Disruptions to cancer screening services have been observed in the majority of settings due to the global coronavirus crisis. Guidelines for cancer screening activities are usually created after a systematic and careful review of the available evidence in an optimal way to provide high quality care and reduce variability in clinical practice. However, the onset of the COVID-19 pandemic required an instantaneous response at a time when the duration of the pandemic could not be predicted and the nature of the virus was still largely unidentified. In the majority of contexts, the consequence of this situation has been a postponement of services limited in time. These disruptions are expected to lead to very advanced cancer diagnoses and deaths over the next few years.
Testing services have now restarted to some extent in most countries; however, after the deadly outbreak of COVID-19, continues to disrupt healthcare delivery. Despite the approval of various safe and highly effective COVID-19 vaccines, supply constraints have delayed their deployment. Therefore, the current disruptions in health care, in general, are expected to remain the same for some time. Hence, the outbreak of the COVID-19 pandemic has had a negative effect on the HPV test and Pap test market.
Based on type, the market is segmented into Pap test and HPV test. The Pap test segment procured the maximum share of global HPV test and Pap test revenue in 2020. This is due to its large-scale implementation in various screening programs. In addition to this, the segment would see a boom with the increase in Pap test awareness initiatives.
Based on application, the market is segmented into cervical cancer screening and vaginal cancer screening. In 2020, the cervical cancer screening segment emerged as the leading segment in the HPV test and Pap test market by obtaining the highest revenue share. The segment would show a promising CAGR during the forecast period. This massive growth and revenue share is attributed to the increasing rates of cervical cancer compared to vaginal cancer.
On the basis of product, the market is segmented into consumables, instruments and services. The consumables segment has acquired the highest revenue share in the HPV and Pap test market, becoming a dominant segment in 2020. This is attributed to its consistently high usage in HPV and cervical screenings. Furthermore, the growth of the segment would be accelerated by the constant development activities of the major market players and the launch of unique consumables, such as tests and kits, for high diagnostic accuracy in HPV and Pap tests.
Outlook end use
On the basis of end use, the market is segmented into hospitals and clinics, laboratories and other end users. Hospitals and clinics segment got the maximum revenue share from the HPV tests and Pap tests market and thus became the leading segment in 2020. This is attributed to the fact that they act as primary care facilities for the diagnosis and treatment of all diseases, such as HPV infections and cervical cancer. In addition to this, the need for hospitals and clinics that offer top quality diagnostic services has been driven by an increase in global healthcare expenditures and constant modification in the healthcare industry.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific and Latin America, Middle East & Africa. North America has emerged as the top region in the global HPV and Pap test market by acquiring the maximum revenue share. The region would show a similar trend even during the forecast period. Some of the catalysts for the growth of the regional market are increased awareness of early diagnosis of cervical cancer, well-planned screening guidelines, and favorable healthcare reimbursement policies.
The market research report covers the analysis of major market players. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Hologic, Inc., Quest Diagnostics, Incorporated, Seegene, Inc., Arbor Vita Corporation, Femasys, Inc. and Qiagen NV
Strategies deployed in the HPV Tests and Pap Tests Market
Nov-2020: Hologic has obtained CE marking in Europe for its Genius digital diagnostic system. It is the first digital cytology platform that integrates a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify precancerous lesions and cancerous cells in women.
September 2020: BD submitted the Premarket Approval (PMA) supplement to the United States Food and Drug Administration (FDA). It is used for the ThinPrep Pap Test PreservCyt Solution vial as an approved specimen type for its BD Onclarity HPV test. The PMA supplement is intended to extend the claims of the sample, which can be used with the BD SurePath vial for the detection of human papillomavirus (HPV) using the BD Onclarity HPV test.
Apr-2020: Roche has received US Food and Drug Administration (FDA) approval for the cobas HPV test. This test is used on fully automated cobas 6800/8800 high throughput systems. The test recognizes women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples.
March 2020: Roche has obtained US Food and Drug Administration (FDA) approval for CINtec PLUS Cytology. This is a first biomarker-based triage test for women with primary cervical cancer screening results positive for human papillomavirus (HPV) using the cobas test 4800 HPV.
April 2018: Hologic announced that the U.S. Food and Drug Administration (FDA) has provided Premarket Approval (PMA) for the ThinPrep Integrated Imager. This imager aims to make automated Pap test imaging more widely available to laboratories and cytologists in the United States.
February 2018: BD received premarket approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity HPV test. This test discovers 14 types of high-risk human papillomaviruses (HPV) from specimens collected for cervical cancer screening (“Pap test”) in the BD SurePath liquid-based cytology vial.
Apr-2017: Roche announced the launch of the Cobas HPV test. This test is used on the Cobas 6800 and Cobas 8800 systems for cervical cancer screening in countries accepting the CE mark.
Scope of the study
Market Segments Covered in the Report:
• Pap test
• HPV test
• Cervical cancer screening,
• Screening for vaginal cancer
By end use
• Hospitals and clinics
• Other end users
• North America
o United States
o Rest of North America
o United Kingdom
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia-Pacific
o Saudi Arabia
o South Africa
o Rest of the LAMEA
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• Becton, Dickinson and company
• Hologic, Inc.
• Quest Diagnostics, built-in
• Seegene, Inc.
• Arbor Vita Corporation
• Femasys, Inc.
• Qiagen SA
• Comprehensive coverage
• The largest number of tables and figures on the market
• Subscription-based model available
• Best price guaranteed
• Provided after-sales research support with 10% free customization
Read the full report: https://www.reportlinker.com/p06131317/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001